menu
    • menu
    [{"orgOrder":0,"company":"Eureka Therapeutics","sponsor":"Cirm","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Funding","leadProduct":"ET140203","moa":"Alpha-fetoprotein receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Eureka Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Intraperitoneal Infusion","sponsorNew":"Eureka Therapeutics \/ Cirm","highestDevelopmentStatusID":"7","companyTruncated":"Eureka Therapeutics \/ Cirm"},{"orgOrder":0,"company":"Eureka Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"ET140203","moa":"Alpha-fetoprotein receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Eureka Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Infusion","sponsorNew":"Eureka Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Eureka Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Eureka Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"ET140203","moa":"Alpha-fetoprotein receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Eureka Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Infusion","sponsorNew":"Eureka Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Eureka Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Eureka Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"ET140203","moa":"Alpha-fetoprotein receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Eureka Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Infusion","sponsorNew":"Eureka Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Eureka Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Eureka Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"ET140203","moa":"Alpha-fetoprotein receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Eureka Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Infusion","sponsorNew":"Eureka Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Eureka Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Eureka Therapeutics","sponsor":"Lyell Immunopharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Series E Financing","leadProduct":"ET140202","moa":"Alpha-fetoprotein","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Eureka Therapeutics","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.050000000000000003,"dosageForm":"Undisclosed","sponsorNew":"Eureka Therapeutics \/ Lyell Immunopharma","highestDevelopmentStatusID":"7","companyTruncated":"Eureka Therapeutics \/ Lyell Immunopharma"},{"orgOrder":0,"company":"Eureka Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"InvisiMask","moa":"SARS-CoV-2 S1","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Eureka Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Eureka Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Eureka Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Eureka Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"ECT204","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Eureka Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eureka Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Eureka Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Eureka Therapeutics","sponsor":"The Division of Cancer Treatment and Diagnosis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Eureka Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Eureka Therapeutics \/ The Division of Cancer Treatment and Diagnosis","highestDevelopmentStatusID":"4","companyTruncated":"Eureka Therapeutics \/ The Division of Cancer Treatment and Diagnosis"},{"orgOrder":0,"company":"Eureka Therapeutics","sponsor":"Memorial Sloan Kettering Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"NDC80","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Eureka Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eureka Therapeutics \/ Memorial Sloan Kettering Cancer Center","highestDevelopmentStatusID":"4","companyTruncated":"Eureka Therapeutics \/ Memorial Sloan Kettering Cancer Center"}]

    Find Clinical Drug Pipeline Developments & Deals by Eureka Therapeutics

    Menu

    Eureka Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Eureka Therapeutics

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed

                            Eureka Therapeutics

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ECT204

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Eureka Advances ARYA-3 Phase II Trial of GPC3-Targeting T-cell Therapy for Liver Cancer

                            Details : ECT204 is an autologous T-cell therapy where T cells are transduced with a lentiviral vector expressing the ECT204 transgene, evaluated for GPC3-positive advanced hepatocellular carcinoma treatment.

                            Product Name : ECT204

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Inapplicable

                            March 18, 2024

                            Lead Product(s) : ECT204

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Eureka Therapeutics

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed

                            Eureka Therapeutics

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ET140203

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Cirm

                            Deal Size : $10.6 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Eureka Therapeutics Awarded $10.6 Million CIRM Grant to Support Clinical Trial of ARTEMIS® T-Cell Therapy in ...

                            Details : The grant will support company's ongoing ARYA-2 Phase I study of ET140203, an autologous T cell-based therapy, for the treatment of pediatric patients with refractory/relapsed liver cancer, including hepatoblastoma, hepatocellular neoplasm not otherwise ...

                            Product Name : ET140203

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            June 06, 2023

                            Lead Product(s) : ET140203

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Cirm

                            Deal Size : $10.6 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Eureka Therapeutics

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed

                            Eureka Therapeutics

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : The Division of Cancer Treatment and Diagnosis

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Eureka Therapeutics Announces License with the National Cancer Institute to Advance GPC2 ARTEMIS® T Cell Ther...

                            Details : The therapy also has expansion potential in medulloblastoma and small cell lung cancer, among several other pediatric and adult cancers that express an abundance of the GPC2 protein on their cell surface.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            October 18, 2022

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : The Division of Cancer Treatment and Diagnosis

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Eureka Therapeutics

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed

                            Eureka Therapeutics

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ET140203

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Eureka Therapeutics Receives Orphan Drug Designations for Treatment of Hepatoblastoma with ET140203 ARTEMIS® ...

                            Details : ET140203 is an investigational therapy during which a patient’s T cells are collected, engineered to express Eureka’s proprietary ARTEMIS® cell receptor and infused back into the patient.

                            Product Name : ET140203

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Inapplicable

                            October 17, 2022

                            Lead Product(s) : ET140203

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Eureka Therapeutics

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed

                            Eureka Therapeutics

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ET140203

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Eureka Therapeutics Receives Orphan Drug Designations for Treatment of Hepatocellular Carcinoma (HCC) With ART...

                            Details : The designation for Eureka’s clinical candidate, ET140203, an investigational therapy TCR-mimic antibody to target alpha-fetoprotein peptide/HLA-A2 complex on liver cancer cells underscore the significant unmet medical need for more effective liver can...

                            Product Name : ET140203

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Inapplicable

                            August 02, 2022

                            Lead Product(s) : ET140203

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Eureka Therapeutics

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed

                            Eureka Therapeutics

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NDC80

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Memorial Sloan Kettering Cancer Center

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Eureka Therapeutics Announces Publication of Study Demonstrating Broad Anti-Tumor Activity of TCR Mimic-Redire...

                            Details : In the study, anti-NDC80 TCRm-redirected T cells demonstrated high specificity in recognizing and killing multiple cancer cell lines. Moreover, no toxicities to healthy leukocytes and hematopoietic stem cells were observed.

                            Product Name : NDC80

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            June 06, 2022

                            Lead Product(s) : NDC80

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Memorial Sloan Kettering Cancer Center

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Eureka Therapeutics

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed

                            Eureka Therapeutics

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ET140203

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Eureka Therapeutics Announces Publication of Crystal Structure of TCR Mimic Redirected T Cells Targeting Alpha...

                            Details : ET140203 T cells are autologous T cells genetically modified to carry a TCR-mimic (TCRm) construct capable of mediating cell killing by targeting tumor specific intracellular antigens and addressing solid tumor therapy challenges.

                            Product Name : ET140203

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Inapplicable

                            March 08, 2022

                            Lead Product(s) : ET140203

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Eureka Therapeutics

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed

                            Eureka Therapeutics

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : InvisiMask

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Eureka Therapeutics Announces Successful Preclinical Results of Invisimask™ Human Antibody Nasal Spray Again...

                            Details : Newly published study reports Invisimask™, a self-administered nasal spray, protects against Sars-Cov-2 infection for up to 10 Hours in mice.

                            Product Name : InvisiMask

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            December 14, 2020

                            Lead Product(s) : InvisiMask

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Eureka Therapeutics

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed

                            Eureka Therapeutics

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ET140203

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Eureka Therapeutics Announces Initiation of ARYA-1 Clinical Trial to Evaluate ET140203 ARTEMIS® T Cell Therap...

                            Details : The ARYA-1 study is a multi-center, open-label, dose escalation clinical trial of ARTEMIS® T cell therapy to initially assess the safety and tolerability of ET140203 T cells in adult patients with AFP-positive HCC and to determine the recommended phase ...

                            Product Name : ET140203

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Inapplicable

                            May 10, 2020

                            Lead Product(s) : ET140203

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Eureka Therapeutics

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed

                            Eureka Therapeutics

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ET140202

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Lyell Immunopharma

                            Deal Size : $45.0 million

                            Deal Type : Series E Financing

                            DEALS_DEV arrow-down

                            Eureka Therapeutics Completes $45 Million Series E Financing

                            Details : The Company will use proceeds to advance its proprietary TCR-mimic and antibody-TCR ARTEMIS® programs, including Eureka’s anti-AFP ARTEMIS® Phase I/II clinical trial in the United States.

                            Product Name : ET140202

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            March 17, 2020

                            Lead Product(s) : ET140202

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Lyell Immunopharma

                            Deal Size : $45.0 million

                            Deal Type : Series E Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth